Thomas Jefferson University

Jefferson Digital Commons
Department of Medical Oncology Faculty
Papers

Department of Medical Oncology

4-26-2022

Cyclophosphamide induces durable molecular and clinical
responses in patients with relapsed T-LGL leukemia.
Zachary Braunstein
Eric McLaughlin
Anjali Mishra
Jonathan E Brammer

Follow this and additional works at: https://jdc.jefferson.edu/medoncfp
Part of the Oncology Commons

Let us know how access to this document benefits you
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital
Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is
a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections
from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested
readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been
accepted for inclusion in Department of Medical Oncology Faculty Papers by an authorized administrator of the
Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.

RESEARCH LETTER

TO THE EDITOR:

Cyclophosphamide induces durable molecular and clinical responses in
patients with relapsed T-LGL leukemia
Zachary Braunstein,1 Eric McLaughlin,2 Anjali Mishra,3,4 and Jonathan E. Brammer5
1
Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH; 2Center for Biostatistics, Department of Biomedical Informatics, The Ohio
State University, Columbus, OH; 3Department of Medical Oncology and 4Department of Cancer Biology, Sydney Kimmel Cancer Center, Thomas Jefferson University,
Philadelphia, PA; and 5Division of Hematology, Department of Internal Medicine, James Comprehensive Cancer Center, The Ohio State University, Columbus, OH

T-cell large granular lymphocytic leukemia (T-LGLL) is a clonal proliferation of cytotoxic T-lymphocytes
with a terminal effectory memory phenotype (CD31/CD81/CD5dim/CD571/CD62L/CD45RA1/
CD45RO2) that can result in severe cytopenias, including neutropenia, anemia, and pancytopenia/bone
marrow failure in severe cases.1-3 The pathogenesis of T-LGLL is thought to be mediated by increased
circulating interleukin-15, and subsequent upregulation of the STAT3 pathway, leading to dysregulation
of apoptosis and resultant cellular proliferation and marrow damage. The management of T-LGLL therefore is immune-suppressive therapy, with methotrexate (MTX), cyclophosphamide (Cy), and cyclosporine
serving as the standard frontline agents. MTX is the standard frontline therapy based off the prospective
ECOG5998 (E5998) study but overall response rate (ORR) was modest at 38%.4 An initial early report
with frontline Cy demonstrated a response rate of 63% in 10/16 patients, including 6 complete response
(CR), though at that time, CR was deﬁned as hematologic CR, and response criteria differed from current
E5998 criteria.5 For patients that fail frontline MTX, oral Cy, with a target dose of 100 mg/day is the standard approach. Data from the ECOG5998 trial suggested an increased ORR with Cy in the second-line
setting, with 21% CR,6 and retrospective data from the French cohort study suggested improved
response rate, with 63% CR,7 when Cy was used second line. More intriguingly, anecdotal evidence suggests that because of its alkylating effects, Cy may eradicate the T-LGLL clone, which has not been
observed with immune-suppressive-based strategies. However, the degree to which a complete molecular
remission (CMR) can be attained, and the lengths of these remissions with Cy remains unknown.
Recently, we published a report on T-LGLL that showed improved clinical responses in patients treated
with Cy, especially if this was used as second line after frontline MTX.8 In that study, 100% of patients
(7/7) that were treated with Cy as second-line therapy after frontline MTX had a response to treatment
(3 CR and 4 partial response [PR]). Here, we report on additional patients (n 5 22) treated with Cy for
relapsed or refractory T-LGLL, and for the ﬁrst time report survival outcomes, duration of response, and
presence of CMR in the relapsed setting.
We retrospectively evaluated all patients treated for T-LGLL with oral Cy at the Ohio State University (OSU)
James Comprehensive Cancer Center from 2000 through 2019. The diagnosis of T-LGLL was made based
on 2016 World Health Organization criteria. T-LGLL criteria included a CD31 CD81 population on ﬂow
cytometry $500 cells/mm3 and a positive monoclonal T-cell receptor (TCR). This was considered positive if
detected by TCR polymerase chain reaction (PCR) or by restriction of TCR-Vbeta noted on ﬂow cytometry.
For patients diagnosed with a clonal TCR by ﬂow cytometry, a panel of 30 TCR-Vbeta rearrangements was
used and considered positive if 1 or more clone was detected in $10% of events. Disease response was
deﬁned by the E5998 study criteria and was conﬁrmed retrospectively by the investigators (Z.B. and J.E.B.).
Although there is variability in follow-up given the retrospective nature of this study, in general, as standard
clinical care, patients were monitored for response on Cy for a minimum of 4 months at the full 100-mg dosage. Standard laboratory values (complete blood count with differential, hepatic function panel, basic chemistry panel) were drawn every 4 to 6 weeks either at OSU or with a local physician. Flow cytometry was
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Table 1. Baseline characteristics of patients attaining CR with cyclophosphamide
Age
at Dx

Sex

Rheumatologic
disease

Prior Tx

Cy line

Cy indication

Max Cy
dose

Time on
Cy, mo

Time before
CR after
starting Cy, mo

Did patient have CMR
(time to CMR, M)?

66

F

RA

CsA (32), MTX

4th

Neutropenia

50 mg BID

11

12

No

66

M

None

MTX

2nd

Anemia

50 mg BID

10

5.5

No

70

F

RA

MTX

2nd

Anemia

50 mg daily

12

5

Yes (7 mo)

67

F

None

MTX (32)

3rd

Anemia and Neutropenia

100 mg daily

13

4

Yes (12 mo)

66

M

None

MTX, BNZ-1

3rd

Neutropenia

100 mg daily

15

5

Yes (11 mo)

65

M

RA

MTX

2nd

Neutropenia

50 mg BID

11

3

No

BID, twice daily; CsA, cyclosporine; Dx, diagnosis; MTX, methotrexate; RA, rheumatoid arthritis; Tx, treatment.

assessed every 2 to 3 months to evaluate for residual disease.
Patients who attained an improvement in their affected blood counts
(ie, neutropenia or anemia) were continued on Cy, even if full E5998
response criteria were not attained because E5998 criteria were
assessed retrospectively only. In this way, patients who attained some
response at 4 months could be evaluated months later to assess for a
deepening of their clinical response. CMR was deﬁned as: CR by
E5998 criteria and clearance of the TCR PCR-based gene rearrangement studies or TCR VBeta ﬂow cytometry assessment for individual
clones. The time-to-response (TTR) was measured as time from start
of Cy until PR or CR, with patients who failed to respond being censored at the end of their Cy treatment. Leukemia-free survival (LFS) in
patients responding to Cy was measured as time from start of Cy until
disease progression, with patients without progression being censored at last follow-up. TTR and LFS were compared across variables
using Kaplan-Meier curves with median survival and 95% conﬁdence
intervals. The OSU’s institutional review board approved this study,
which was conducted in accordance with the Declaration of Helsinki.
Twenty-two patients with relapsed/refractory T-LGLL, with an average duration of 8 months (range, 1-15) of Cy treatment, and a
median follow-up time of 24.4 months, were included in this analysis.
Thirteen patients (59%) were treated with Cy as second line and 9
(41%) as third line or greater. Standard dosing included an initial
dose of 50 mg daily for 2 weeks with increase to 100 mg if tolerated
for 4 months. Cy was dosed at 150 mg (1 patient), 100 mg (17
patients), and 50 mg (3 patients), whereas 1 patient received 1260
mg for multiple myeloma. Assessment for clonal hematopoiesis
(CHIP) or associated mutations was not routinely evaluated. As part
of our standard panel, mutations were assessed in 11/22 (50%)
patients because this panel became available for T-LGLL only in
2018. Four patients had no mutations, and 7 patients were found to
have the following mutations (2 patients had 2 separate mutations):
STAT3 (35), CARD11, NOTCH2, SF3B1, and DNMT3A. Two
patients were found to have 2 separate mutations, 1 with CARD11/
NOTCH2 and another with STAT3 (D661Y)/SF3B1. Of the STAT3
mutations, 3 patients had a D661Y mutation, 1 had a D661V mutation, and 1 had an N647I mutation. Overall, 11 patients were tested
for STAT3 mutations because this was only routinely done after
2018. Of those 11 patients, 5 (45%) were found to have a STAT3
mutation (supplemental Table 1). Of these, 4 patients with a STAT3
mutation had no response to Cy and 1 patient had a PR to Cy (this
patient also had an SF3B1 mutation) (supplemental Table 1). At the
low doses of Cy used for T-LGLL, Cy is generally very well tolerated,
with only minor toxicities, including nausea, cytopenias, and fatigue.
In our cohort of patients, the most common side effect observed
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was grade 1 fatigue (n 5 2). We also observed grade 1 dizziness
(n 5 1) and 1 patient with grade 1 leukopenia.
For relapsed/refractory T-LGLL, the ORR was 68% (15/22) with 6
CR (27%) and 9 PR (41%). At the 4-month mark, the ORR was
27% (2 CR, 4 PR). The median time to response was 5.6 months
for CR and 5.8 months for PR. Three patients that had a PR at the
4-month mark later converted to a CR. The median time to maximum
response TTRMax (CR or PR) was 6 months (95% conﬁdence
interval, 4-7), whereas median time to PR and CR were 9 and 7
months, respectively. Baseline characteristics of those achieving CR
can be seen in Table 1. Interestingly, of the 6 patients that achieved
a CR, 50% had a CMR with durable eradication of their T-cell
clone. Among responders, the median follow-up time was 27
months and the median LFS was 24 months. Of note, among those
with a CR, median follow-up is slightly longer at 28.5 months.
When broken down by type of response, the median LFS for those
with PR was 27 months, whereas the median LFS for those with
CR was not reached as no patients progressed. Additionally, for
patients that achieved a CMR, the LFS has not yet been reached.
Here we report that patients receiving Cy for relapsed T-LGLL can
attain durable remissions, including CMR, with a prolonged duration
of response with long-term follow-up. Previous reports have focused
on response rates of Cy but have not evaluated the duration of
response in these patients, and no studies have reported CMR in
patients with relapsed/refractory T-LGLL. Of particular interest is
that no patients who attained a CR have relapsed, demonstrating
durable remissions are attainable with Cy in relapsed T-LGLL. We
also demonstrate that a CMR is attainable in refractory patients with
Cy, which has previously only been shown in patients that were
treated with Cy frontline.9 Importantly, we demonstrate that there
was signiﬁcant consolidation of response after the initial 4-month
treatment period, with an ORR of 27% at 4 months, but an ORR of
64% in long-term follow-up. These novel results suggest that
patients should remain on Cy beyond initial response because Cy
can deepen the clinical response over time. To assess for response,
we recommend checking for the TCR (by PCR of ﬂow cytometry)
every 3 months while on treatment to assess for response and CMR.
The standard approach at OSU is to treat patients with Cy for a maximum of 12 months because of the increased risk of mutagenesis,
myelodysplasia, or marrow injury resulting from prolonged Cy.10-13
This also seems adequate time to attain a maximum response, as the
median TTRMax (CR or PR) in our study was 6 months, and most
patients responded by 8 months. However, 4 patients continued
treatment beyond 12 months solely at the discretion of their local
26 APRIL 2022 • VOLUME 6, NUMBER 8

physician, outside of OSU recommendations, with 2 patients on Cy
for 13 total months, 1 for 14 months, and 1 for 15 months. Our data
clearly demonstrate that maximal response is typically obtained by
8 months of treatment, and that these responses are durable, with
no long-term relapses in patients with CR or CMR.
We acknowledge certain limitations of this study. No CR patients
had pancytopenia, which can result in selection bias in a small population of patients with CR. Further, long-term follow-up is needed
to assess the duration of remission, and impact of CMR on patients
with relapsed T-LGLL treated with Cy. Clonal hematopoiesis (CHIP)
mutations were also not routinely evaluated, and in these patients,
caution should be used when initiating treatment with Cy. Further,
the clinical and prognostic signiﬁcance of STAT3 mutations and the
response to Cy will need to be evaluated in future prospective studies. Although our results strongly suggest that Cy can produce
durable remissions, and CMR, these ﬁndings will need to be further
validated in a larger cohort in future prospective randomized studies,
including the use of CMR as a novel endpoint in T-LGLL. Nevertheless, our results demonstrate that Cy induces durable responses in
the setting of relapsed T-LGLL, including CMRs. Pending future
studies, we suggest that Cy should be maintained for up to 8 to 12
months to consolidate response, with the goal of attaining a CR or
CMR. Further, CMR, as a component of response criteria, should
be incorporated in the design of future clinical trials.
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